SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-14-411349
Filing Date
2014-11-13
Accepted
2014-11-13 17:13:28
Documents
13
Period of Report
2014-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d778784d10q.htm 10-Q 729143
2 EX-10.1 d778784dex101.htm EX-10.1 113038
3 EX-10.2 d778784dex102.htm EX-10.2 23509
4 EX-31.1 d778784dex311.htm EX-31.1 7809
5 EX-31.2 d778784dex312.htm EX-31.2 7820
6 EX-32.1 d778784dex321.htm EX-32.1 3900
7 EX-32.2 d778784dex322.htm EX-32.2 3750
  Complete submission text file 0001193125-14-411349.txt   5678876

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE DOCUMENT rvnc-20140930.xml EX-101.INS 698207
9 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20140930.xsd EX-101.SCH 59091
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rvnc-20140930_cal.xml EX-101.CAL 82994
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvnc-20140930_def.xml EX-101.DEF 242799
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20140930_lab.xml EX-101.LAB 458740
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20140930_pre.xml EX-101.PRE 340633
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 141219276
SIC: 2834 Pharmaceutical Preparations